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ABSTRACT: The adducts formed between trans-dimethyla-
mine methylamine dichlorido platinum(II), [t-
PtCl2(dma)(ma)], and two model proteins i.e. hen egg white ly-
sozyme (HEWL) and bovine pancreatic ribonuclease (RNase 
A), were independently characterized by X-ray crystallography 
and ESI mass spectrometry. In these adducts the Pt(II) center, 
upon chloride release, coordinates either to His or Asp residues 
while both alkyl amino ligands remain bound to the metal. 
Comparison with the cisplatin derivatives of the same proteins 
highlights for [t-PtCl2(dma)(ma)] a kind of biomolecular meta-
lation remarkably different from cisplatin. The implications of 
these results are briefly discussed. 
Since the discovery of the antitumor activity of cisplatin and 
the establishment of the so called “Hoeschele’s rules” defining 
structure-activity relationships in cytotoxic platinum(II) 
complexes, the presence of a cis configuration with two 
adjacent  leaving ligands has been considered an absolute 
requirement for the anticancer action. For this reason, trans-
Pt compounds have long been reputed as uninteresting and 
largely neglected afterward. This trend was reversed in more 
recent times when it was realised that a number of trans-Pt 
compounds, including  trans-[PtCl2{EHN=C(OCH3)CH3}2], 
trans-[PtCl2(NH3) (thiazole)], trans-dimethylamine 
methylamine dichloro Pt(II) [t-PtCl2(dma)(ma)] and trans-
isopropylamine dimethylamine dichlorido platinum(II) [t-
PtCl2(ipa)(dma)] manifest remarkable cytotoxic properties 
towards several human tumor cell lines1-3. It was found  that 
the presence of bulky amino ligands within trans square 
planar platinum(II) configuration leads to a net decrease in 
reactivity with biomolecules, commonly associated with a 
higher antitumor activity in vitro3. 
 Interactions of Pt-containing drugs with proteins are 
believed to play key roles in drug resistance processes and also 
in the mechanism of action of this class of compounds4-6. 
However, the formation of adducts between trans-Pt(II) 
compounds and proteins and their biological consequences 
have been poorly investigated so far4-6.  
To elucidate this issue in more depth, we describe here the 
X-ray structure of the HEWL/[t-PtCl2(dma)(ma)] derivative 
and that of the adduct formed between the same Pt compound 
and RNase A. We have chosen these two proteins since they 
have been used for more than half a century as model systems 
for studies on protein chemistry, including metalation caused 
by metal-based bioactive agents7,8, like cisplatin7a,8a. The struc-
tural characterization is supported and completed by inde-
pendent ESI mass spectrometry measurements. 
Crystals of the HEWL/[t-PtCl2(dma)(ma)] adduct were 
obtained by cocrystallization experiments, using 0.6 M 
NaNO3, 20% ethylene glycole and 0.1 M sodium acetate, at pH 
4.2, as reservoir solution. Details of the crystallization 
procedure, data collection, structure determination and 
refinement statistics are given in the SI, Table S1 and S2. The 
structure, which has been solved at 2.5 Å resolution, refines to 
R factor = 17.9 (Rfree = 25.9). The overall HEWL structure in 
the adduct is very similar to that of the ligand-free enzyme 
(PDB code 193L)9: the root mean square deviation in positions 
of CA atoms is as low as 0.3 Å. The inspection of the electron 
density maps revealed platination of the only HEWL histidine 
residue, i.e. His15, at imidazole NE2 atom (at the so-called left-
handed site)7a  (Figure 1). Pt(II) has an occupancy equal to 0.8 
and is also bound to other three light atoms, which have been 
interpreted as two nitrogens of two amine moieties and to a 
water molecule. The His(N)-Pt distance is 2.3 Å, whereas Pt-N 
distances are close to 2.0  Å. The geometry of this site is 
significantly distorted. 
The X-ray structure also reveals the presence of an addi-
tional binding site close to Asp101 (Figure 1). In this site, Pt(II) 
has an occupancy of 0.35. The Asp(OD1)-Pt distance is 2.1 Å, 
whereas Pt-N distances are close to 2.0  Å. 
In both Pt binding sites, the quality of the electron density 
maps does not permit to gain conclusive information on the 
 nature of Pt ligands. Therefore, electrospray ionization (ESI) 
mass spectra were registered to obtain further, independent 
information on the same adduct. In particular, HEWL was 
dissolved in a suitable buffer (20 mM ammonium acetate 
buffer, pH 6.8) and treated with a 3:1 excess of a fresh solution 
of the Pt compound. Then, ESI mass spectra were recorded 
after increasing time intervals (Figure 2a). Formation of 
metallodrug-protein adducts is well witnessed by the 
appearance of two main peaks of greater molecular mass than 
the native protein. Interestingly, these two peaks -that may be 
attributed to the same  platinum adduct- show values of 
14609.83 and 14633.87 Da (i.e. the previous peak plus a Na+ 
ion), suggesting the formation of an adduct where the Pt 
compound loses one Cl ligand, retaining the dma and ma 
ligands. Adduct formation is nearly complete after the first 24 
h; no relevant further changes are detected at 72 h.  
 
Figure 1. Cartoon representation of the adduct between HEWL and t-
PtCl2(dma)(ma). The side chains of His15 and Asp101, which are exposed to the 
solvent, are shown along with Pt and its ligands. 2Fo-Fc electron density maps 
are contoured at 3σ level. The structure has been deposited in the Protein Data 
Bank under the accession code 4QGZ. 
A similar approach was used to monitor the interactions of  
[t-PtCl2(dma)(ma)] with RNase A. Crystals of the metallodrug-
protein complex were obtained by soaking experiments. 
Ligand-free RNase A crystals grown by hanging drop vapour 
diffusion method using 20% PEG4000, 10 mM sodium citrate 
pH 5.0 and protein concentration 20 mg mL-1 were incubated 
for five days with an excess of the Pt compound at 1:10 protein 
to metal molar ratio. X-ray diffraction data were collected on 
these crystals at 2.00 Å resolution. Details of crystallization, 
data collection and structure refinement are given in the SI 
and in Tables S1 and S2.  
The structure of this adduct, which contains two molecules 
in the asymmetric unit (Figure S1), refines to Rfactor = 21.4 
(Rfree = 27.5). The overall structure of the RNase A molecules 
in the complex is very similar to that of the ligand-free protein 
(PDB code 1JVT)10: the root mean square deviations in CA 
atom positions are in the range 0.4-0.6 Å. Platination just 
induces some conformational disorder of residues 16-22 in 
molecules A and B.  
In both molecules, platination occurs at the NE2 atom of 
the imidazole ring of His105 (occupancy = 1.0) and at the ND1 
atom of His48 (occupancy = 0.3 and 0.4 for molecule A and B, 
respectively). Moreover, platination also occurs at His119 i.e. 
at the enzyme active site (Figure 3A).  In molecule A, platina-
tion occurs at ND1 and NE2 atoms of imidazole ring of His119 
(occupancy 0.3 and 0.4, respectively), which adopts two con-
formations. Also in molecule B platinated His119 adopts two 
distinct conformations and in both cases Pt binds NE2 atom 
(Pt occupancy 0.5 and 0.5, respectively).  
Notably, the whole Pt-compound has been modelled at the 
His105 binding site (Figure 3b). In this site, His(N)-Pt distance 
is equal to 2.3 Å, whereas Pt-N distances are close to 1.9 Å. The 
fourth loosely coordinated ligand of the Pt, placed at 2.6 Å, has 
been modelled as a water molecule, suggesting that the reac-
tive species, in the conditions used to obtain RNase A/[t-
PtCl2(dma)(ma)] adduct, is the product of the hydrolysis of t-
PtCl2(dma)(ma). In the other binding sites, a water molecule 
is found 2.8-3.0 Å far apart from the metal. 
A direct comparison between the structure of the RNase 
A/[t-PtCl2(dma)(ma)] derivative and that of the same protein 
in complex with cisplatin8a demonstrates that trans Pt-com-
pounds are able to induce a type of protein metalation re-
markably distinct from that inferred by cisplatin. In fact, we 
have shown that cisplatin binds RNase A through Met29 co-
ordination.8a It seems that [t-PtCl2(dma)(ma)] is not able to 
bind Met29 probably due to the greater steric hindrance of the 
alkyl amine groups compared to amino groups. These results 
are in line with previous studies showing that transplatin and 
cisplatin have distinct binding sites upon reaction with ubiq-
uitin.11 
Even in the case of RNase A, ESI-MS analyses have been 
carried out. The ESI mass spectra show two main peaks at 
14011.31 and 14340.38 Da (Figure 2b) that were attributed to 
mono and bis coordination, respectively, of the same metallic 
fragment where the Pt center loses a single chloride ligand (in 
both cases these peaks are accompanied by the respective Na+ 
species).  
a 
 
 b
Figure 2. Deconvoluted ESI mass spectra of 10-4 M HEWL (a) and RNase (b) 
treated with [t-PtCl2(dma)(ma)] (metal:protein ratio = 3:1) in 20 mM ammonium 
acetate (pH 6.8) buffer recorded after 24 (A) and 72h (B) of incubation at 37°C. 
In spite of the fact that the same type of Pt coordination is 
afforded with the two proteins, a greater amount of adduct is 
formed in the case of RNase A (see Figure 2). 
a  
b  
Figure 3. a) Cartoon representation of the adduct between RNase A and t-
PtCl2(dma)(ma). The side chains of His48, His105 and His119 are shown along 
with Pt and its ligands. The structure has been deposited in the Protein Data 
Bank under the accession 4QH3. b) A zoom on His105 of molecule A. 2Fo-Fc 
electron density maps are shown at 1.5 σ level. A scheme showing the coordina-
tion around central Pt ion after coordination to His105 is reported in SI (Figure 
S2). 
Although some differences are found upon comparing data 
obtained from ESI mass spectra with those from X-ray 
diffraction experiments (which may be easily accounted for 
upon considering the different conditions of the two 
experiments); the obtained results demonstrate that alkyl 
amine ligands are invariantly retained upon reacting the 
platinum drug with proteins. 
 In conclusion, we have offered here unambiguous 
structural evidence that the trans-dimethylamine 
methylamine dichloro Pt(II) complex gives rise to stable 
adducts with two different model proteins. These adducts are 
formed through His or Asp binding of a [Pt (RNH2)2Cl]+ or [Pt 
(RNH2)2OH2]2+ fragment (Figure S2), i.e. the products of the 
hydrolysys of the original compound in water. These 
structures grow the crystallographic repertoire of Pt adducts 
with proteins and represent the first high resolution 
characterization for adducts formed between trans-Pt 
compounds and proteins. Our data in combination with 
previous ones3 reveal that trans-Pt compounds do bind 
proteins with full retention of the alkyl amine Pt ligands. The 
retention of nitrogen ligands in the reaction of trans-Pt 
complexes with proteins is in agreement with a recent study 
describing the interactions of other trans-Pt compounds with 
the Atox-1 protein12.  
As expected, based on results from our previous studies of 
interactions between this Pt complex with oligonucleotides 
[13], this kind of biomolecular metalation may result in 
different patterns of DNA platination when compared to 
cisplatin and its analogues and, accordingly, in a different 
pharmacological profile.  
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